AstraZeneca has closed the previously announced $1.8 billion acquisition of US biopharmaceutical company CinCor Pharma. Under the terms of the agreement, AstraZeneca acquired all outstanding shares as well as the cash and marketable securities of CinCor Pharma for approximately $1.3bn upfront and around $500 million, respectively. Last month, AstraZeneca announced a definitive agreement to acquire […]
AstraZeneca has agreed to acquire CinCor Pharma for a transaction value of around $1.8 billion, which includes an upfront cash payment of about $1.3 billion, plus potential contingent payment on regulatory submission of the latter’s baxdrostat product. Under the merger agreement, the British-Swedish biotechnology company will initiate a tender offer by 23 January 2023 to […]
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) and reduced ejection fraction (HFrEF). This marks a significant step forward in the treatment options available […]
AstraZeneca has been granted breakthrough therapy designation (BTD) for Farxiga (dapagliflozin) from the US Food and Drug Administration (FDA) for the treatment of patients with chronic kidney disease (CKD), irrespective of type 2 diabetes (T2D). According to the US Centers for Disease Control and Prevention (CDC), chronic kidney disease is a serious, progressive condition defined […]
AstraZeneca has secured fast track designation for Farxiga (dapagliflozin) in the US for its use in reducing the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults after an acute myocardial infarction (MI) or heart attack. The fast track designation for the oral once-daily sodium-glucose co-transporter-2 (SGLT2) inhibitor is based on […]